Sugi Predict

Sugi Predict / Compounds / SCHEMBL7797061

SCHEMBL7797061

SCHEMBL7797061

O=C(O)c1cccc(C2(C(F)(F)F)N=N2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 1/20 0.44
▸ AKR1C2 P52895 1/20 0.44
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA6 P23280 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ PDK2 Q15119 2/20 0.42
▸ GABRA1 P14867 3/20 0.41
▸ GABRG2 P18507 3/20 0.41
▸ GABRB3 P28472 3/20 0.41
▸ GABRB2 P47870 2/20 0.41
▸ KMO O15229 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ SRD5A2 P31213 1/20 0.41
▸ KIF11 P52732 1/20 0.40
▸ ADRA2A P08913 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30192521 1.00 AKR1C3 (0.44) AKR1C3AKR1C2CA12CA1CA2
SCHEMBL12985400 0.81 PDK2 (0.46) PDK2
SCHEMBL19079671 0.81 GABRA1 (0.43) PDK2GABRA1GABRG2GABRB3GABRB2
SCHEMBL22587363 0.80 ADRA2A (0.49) GABRA1GABRG2GABRB3GABRB2KIF11
SCHEMBL2380170 0.79 KIF11 (0.51) CA12CA1CA2CA6CA9
SCHEMBL12986388 0.78 GABRA1 (0.47) CA12CA1CA2CA9PDK2
SCHEMBL16131354 0.77 PDK2 (0.44) AKR1C3AKR1C2CA12CA1CA2
SCHEMBL28168249 0.77 KDM4C (0.46) AKR1C3AKR1C2CA12CA1CA2
SCHEMBL16050167 0.76 AKR1B1 (0.43) GABRA1GABRG2GABRB3GABRB2CYP1A2
SCHEMBL5497635 0.75 POLB (0.40) CA12CA1CA2CA9PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250257041-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2025-08-14 — — US disclosed
EP-4526291-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER The Board of Regents of the University of Texas System (US) 2025-03-26 — — EP disclosed
WO-2023225327-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-11-23 — — WO disclosed
EP-2694509-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES PFIZER LTD (GB) 2016-05-18 — — EP disclosed
EP-2694509-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES PFIZER LTD (GB) 2016-05-18 — — EP disclosed
US-20160031935-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF NUCHEM THERAPEUTICS (CA) 2016-02-04 — — US disclosed
EP-2961765-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF Adaerata, Limited Partnership (CA) 2016-01-06 — — EP disclosed
US-20140364415-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (GB) 2014-12-11 — — US disclosed
US-20140364415-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (GB) 2014-12-11 — — US disclosed
US-8846698-B2 Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors PFIZER LIMITED (US) 2014-09-30 — — US disclosed
US-20120258950-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (GB) 2012-10-11 — — US disclosed
US-20120258950-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (GB) 2012-10-11 — — US disclosed
WO-2012137089-A1 PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES PFIZER LIMITED (GB) 2012-10-11 — — WO disclosed
WO-2012137089-A1 PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES PFIZER LIMITED (GB) 2012-10-11 — — WO disclosed
US-20010027248-A1 Novel receptor SMITHKLINE BEECHAM P.L.C. 2001-10-04 — — US disclosed
US-6245893-B1 ANTICONVULSANTS, USE IN TREATMENT OR PREVENTION OF NERVOUS SYSTEM DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2001-06-12 — — US disclosed
US-5985334-A Screening methods to identify anti-convulsant compounds SMITHKLINE BEECHAM P.L.C. (GB) 1999-11-16 — — US disclosed
CN-1175262-A Novel receptor SMITHKLINE BEECHAM PLC (GB) 1998-03-04 — — CN disclosed
EP-0807122-A1 NOVEL RECEPTOR SMITHKLINE BEECHAM PLC (GB) 1997-11-19 — — EP disclosed
WO-1996018650-A1 NOVEL RECEPTOR SMITHKLINE BEECHAM P.L.C. (GB) 1996-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257041-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER DDIT3, ATF4, EIF2AK3 AKR1C3 3318/4885AKR1C2 3370/4885CA12 4559/4885
US-20140364415-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS DMPK, DTYMK, MUSK AKR1C3 3909/4885AKR1C2 3730/4885CA12 4869/4885
US-20010027248-A1 Novel receptor ADGRF1, TACR2, GPR4 AKR1C3 2833/4885AKR1C2 2703/4885CA12 4561/4885
US-20120258950-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS DMPK, DTYMK, MUSK AKR1C3 3909/4885AKR1C2 3730/4885CA12 4869/4885
US-20160031935-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 AKR1C3 1146/4885AKR1C2 889/4885CA12 1401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.